EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and Application of a Pseudovirus-Based Assay for Modelling SARS-CoV-2 Spike Protein Mediated Drug Screening

Shokhrukh A Khasanov iD, Iana L Esaulkova iD, Alexandrina S Volobueva, Alexander V Slita, Daria V Kriger iD, Dmitri Tentler iD, Olga I Yarovaya iD, Anastasia S Sokolova, Andrey N Gorshkov, Anna S Dolgova iD, Irina N Lavrentieva, Vladimir G Dedkov iD und 2 weitere

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27020791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Shokhrukh A Khasanov und 13 weiteren Autor:innen. Beteiligte Einrichtung: Saint Petersburg Pasteur Institute, Federal Service for the Oversight of Consumer Protection and Welfare, 197101 Saint Petersburg, Russia. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Antiviral Agents. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), St. Petersburg Pasteur Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Requirements for novel effective antiviral agents against SARS-CoV-2 emphasizes the importance of robust in vitro screening platforms. We developed a test system based on spike-pseudotyped lentiviruses, carrying either luc+ or EGFP reporter genes as a payload, and a human non-small cell lung carcinoma (NSCLC) cell line, overexpressing ACE2 (H1299-hACE2). The cell origin makes our system resemble lung epithelium infection. Transmission electron microscopy confirmed that the spike glycoproteins on the pseudotyped lentiviral particles resemble native SARS-CoV-2 spike glycoproteins, thus validating their use in inhibitor screening. H1299-hACE2 cells showed significantly higher infection rate (p < 0.005) with spike-pseudotyped lentiviruses compared to parental H1299 cells, as determined by luciferase and fluorescence assays. The susceptibility of the stable H1299-hACE2 cell line to a broad panel of SARS-CoV-2 variants (Wuhan, Beta, Delta, Omicron) was assessed here for the first time in a unified experimental setting. Infection of H1299-hACE2 cells with SARS-CoV-2 induced cell fusion and syncytium formation with subsequent cell death. The developed pseudovirus-based assay was further used for assessment of the antiviral properties of derivatives of 1,7,7-trimethyl-[2.2.1]-bicycloheptane-potential spike protein inhibitors, which possess moderate activity against lentiviral particles. The H1299-hACE2/spike-pseudotyped lentivirus assay is, therefore, a reliable, high-efficiency platform for screening spike-mediated entry inhibitors. The cell line obtained during the development of the platform can be used to isolate and study new variants of SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Antiviral AgentsHumansLentivirusDrug Evaluation, PreclinicalAngiotensin-Converting Enzyme 2Cell Line, TumorViral PseudotypingCOVID-19 Drug TreatmentCOVID-19

Stichwörter der Autor:innen

ACE2H1299SARS-CoV-2antiviralscoronaviruslentiviruspseudotypingspike protein

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antiviral AgentsAngiotensin-Converting Enzyme 2ACE2 protein, human

Autor:innen und Institutionen

  • Saint Petersburg Pasteur Institute, Federal Service for the Oversight of Consumer Protection and Welfare, 197101 Saint Petersburg, Russia.
  • Division of Pediatric Infectious Diseases, Rambam Health Care Campus, Haifa 3109601, Israel.
  • Institute of Cytology, Russian Academy of Sciences, 194064 Saint Petersburg, Russia.
  • G-INCPM, the Weizmann Institute of Science, Rehovot 7610001, Israel.
  • N. N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, 630090 Novosibirsk, Russia.
  • A. A. Smorodintsev Influenza Research Institute, 197376 Saint Petersburg, Russia.

ORCID-Profile: Shokhrukh A Khasanov, Iana L Esaulkova, Daria V Kriger, Dmitri Tentler, Olga I Yarovaya, Anna S Dolgova, Vladimir G Dedkov, Vladimir V Zarubaev

Förderung

  • Ministry of Science and Higher Education of the Russian Federation
  • Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
  • St. Petersburg Pasteur Institute

Zitieren

APA

Khasanov, S. A., Esaulkova, I. L., Volobueva, A. S., Slita, A. V., Kriger, D. V., Tentler, D., Yarovaya, O. I., Sokolova, A. S., Gorshkov, A. N., Dolgova, A. S., Lavrentieva, I. N., Dedkov, V. G., Salakhutdinov, N. F., & Zarubaev, V. V. (2026). Development and Application of a Pseudovirus-Based Assay for Modelling SARS-CoV-2 Spike Protein Mediated Drug Screening. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27020791

Vancouver

Khasanov SA, Esaulkova IL, Volobueva AS, Slita AV, Kriger DV, Tentler D, et al. Development and Application of a Pseudovirus-Based Assay for Modelling SARS-CoV-2 Spike Protein Mediated Drug Screening. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27020791

BibTeX
@article{Khasanov2026,
  author = {Khasanov, Shokhrukh A and Esaulkova, Iana L and Volobueva, Alexandrina S and Slita, Alexander V and Kriger, Daria V and Tentler, Dmitri and Yarovaya, Olga I and Sokolova, Anastasia S and Gorshkov, Andrey N and Dolgova, Anna S and Lavrentieva, Irina N and Dedkov, Vladimir G and Salakhutdinov, Nariman F and Zarubaev, Vladimir V},
  title = {Development and Application of a Pseudovirus-Based Assay for Modelling SARS-CoV-2 Spike Protein Mediated Drug Screening},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27020791}
}
Kostenlos starten →